Abstract
Besides the importance of the renin-angiotensin system (RAS) in the circulation and other organs, the local RAS in the kidney has attracted a great attention in research in last decades. The renal RAS plays an important role in the body fluid homeostasis and long-term cardiovascular regulation. All major components and key enzymes for the establishment of a local RAS as well as two important angiotensin II (Ang II) receptor subtypes, AT1 and AT2 receptors, have been confirmed in the kidney. In addition to renal contribution to the systemic RAS, the intrarenal RAS plays a critical role in the regulation of renal function as well as in the development of kidney disease. Notably, kidney AT1 receptors located at different cells and compartments inside the kidney are important for normal renal physiological functions and abnormal pathophysiological processes. This mini-review focuses on: 1) the local renal RAS and its receptors, particularly the AT1 receptor and its mechanisms in physiological and pathophysiological processes, and 2) the chemistry of the selective AT1 receptor blocker, losartan, and the potential mechanisms for its actions in the renal RAS-mediated disease.
Keywords: AT1 blocker, renal RAS, renal remodeling, losartan
Current Medicinal Chemistry
Title: Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney
Volume: 16 Issue: 28
Author(s): Feichao Xu, Caiping Mao, Yujuan Liu, Lei Wu, Zhice Xu and Lubo Zhang
Affiliation:
Keywords: AT1 blocker, renal RAS, renal remodeling, losartan
Abstract: Besides the importance of the renin-angiotensin system (RAS) in the circulation and other organs, the local RAS in the kidney has attracted a great attention in research in last decades. The renal RAS plays an important role in the body fluid homeostasis and long-term cardiovascular regulation. All major components and key enzymes for the establishment of a local RAS as well as two important angiotensin II (Ang II) receptor subtypes, AT1 and AT2 receptors, have been confirmed in the kidney. In addition to renal contribution to the systemic RAS, the intrarenal RAS plays a critical role in the regulation of renal function as well as in the development of kidney disease. Notably, kidney AT1 receptors located at different cells and compartments inside the kidney are important for normal renal physiological functions and abnormal pathophysiological processes. This mini-review focuses on: 1) the local renal RAS and its receptors, particularly the AT1 receptor and its mechanisms in physiological and pathophysiological processes, and 2) the chemistry of the selective AT1 receptor blocker, losartan, and the potential mechanisms for its actions in the renal RAS-mediated disease.
Export Options
About this article
Cite this article as:
Xu Feichao, Mao Caiping, Liu Yujuan, Wu Lei, Xu Zhice and Zhang Lubo, Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney, Current Medicinal Chemistry 2009; 16 (28) . https://dx.doi.org/10.2174/092986709789105000
DOI https://dx.doi.org/10.2174/092986709789105000 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes
Current Diabetes Reviews Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Progress in the Discovery of BACE Inhibitors
Current Pharmaceutical Design Sildenafil and Cardioprotection
Current Pharmaceutical Design Gestational Diabetes Mellitus Pharmacological Prevention and Treatment
Current Pharmaceutical Design Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Current Molecular Medicine Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review
Current Neuropharmacology Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Dosing of Antibiotics in Critically Ill Patients Undergoing Renal Replacement Therapy
Current Pharmaceutical Biotechnology Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis?
Current Drug Targets - Cardiovascular & Hematological Disorders Hyperandrogenism, Insulin Resistance and Hyperinsulinemia as Cardiovascular Risk Factors in Diabetes Mellitus
Current Diabetes Reviews Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens
Current Drug Safety Impact of Pre-Diabetes and Diabetes on Cardiovascular Outcomes
Current Vascular Pharmacology The Role of ROS and RNS in Regulating Life and Death of Blood Monocytes
Current Pharmaceutical Design Pathophysiology of Atherosclerotic Plaque Development
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents
Current Pharmaceutical Design Hypertension in 2017: Update in Treatment and Pharmaceutical Innovations
Current Pharmaceutical Design Metabolic Syndrome and Diabetic Atherothrombosis: Implications in Vascular Complications
Current Molecular Medicine The Inflammation Paradigm and Coronary Artery Disease: What Celsus, Virchow and Gene Knock Outs Have Taught Us
Cardiovascular & Hematological Disorders-Drug Targets The Update of NGAL in Acute Kidney Injury
Current Protein & Peptide Science